Latest Ai Development News

Echo IQ has locked in a strategic $20 million investment and US partnership with Pro Medicus, alongside a $110 million capital raise, positioning the company for accelerated commercial expansion of its AI-driven cardiovascular diagnostics in the US.

Integrated Research (ASX: IRI) reported a 13-17% decline in pro forma revenue for FY26, weighed down by a softer renewals book and weaker new business in H2. Despite this, cash reserves rose 27%, underpinning ongoing investment in the company’s product-led growth strategy.

Optiscan Imaging has fast-tracked Stage 2 of its pioneering head and neck cancer imaging study, moving into live intraoperative imaging ahead of schedule. This advancement supports FDA regulatory efforts and enhances the company’s AI imaging development.

Stakk Limited is set to become a global powerhouse in AI-driven Digital Trust infrastructure following its US$63 million acquisition of ParaScript, a leader in AI-powered document intelligence and fraud detection. The deal significantly boosts Stakk's scale, technology, and recurring revenue base, underpinning a robust growth trajectory.

Echo IQ has locked in a pivotal exclusive data licensing deal with Advara HeartCare, gaining access to as many as one million de-identified echocardiography studies, a move set to turbocharge its cardiovascular AI development.

Whitefield Industrials delivered a $21.1 million net profit for FY2026, upheld its long-standing dividend track record, and outperformed its benchmark despite geopolitical tensions and market volatility.

Aerometrex has secured two lucrative off-the-shelf data contracts worth AUD 1.07 million from AI innovators Zeromatter Technologies and Neara, underscoring its growing role as a key provider of spatial datasets for AI training.

dorsaVi has secured exclusive rights to two key robotics patents from NTU Singapore, filling critical gaps in safety control and data acquisition to expand into collaborative robotics and exoskeleton markets.

Janison Education Group has wrapped up its largest FY26 assessment programs including NAPLAN and its first New Zealand Ministry of Education event, while progressing AI capabilities and navigating a $3 million revenue impact from exiting NSW venue hire services.

Optiscan Imaging has submitted its FDA dossier for InSpecta®, marking a crucial step toward US veterinary market entry, while progressing clinical studies for InVue® and InForm® ahead of further FDA submissions in 2026.

Oneview Healthcare boosted its cash reserves to €10.3 million by completing a significant capital raise and is progressing its AI-powered Care Assistant, Ovie, with pilot deployments planned for 2026.

Temple & Webster is reshaping its leadership with co-founder Mark Coulter stepping down as CEO to become Executive Chair, while former executive Susie Sugden returns to helm the company from July 2026.